AWM
TGTX icon

Avior Wealth Management’s TG Therapeutics TGTX Stock Holding History

Avior Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17
Closed -$511 – 2179
2024
Q4 		$511 Buy
+17
New +$488 ﹤0.01% 2284
2024
Q2 		– Sell
-269
Closed -$4.09K – 3589
2024
Q1 		$4.09K Buy
+269
New +$4.29K ﹤0.01% 2128
2021
Q4 		– Sell
-18,091
Closed -$602K – 1220
2021
Q3 		$602K Buy
18,091
+3,874
+27% +$120K 0.05% 273
2021
Q2 		$551K Buy
+14,217
New +$558K 0.06% 286

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Avior Wealth Management's TGTX Position: Q1 2025 in Review

Avior Wealth Management sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 17 shares — an estimated $511 sold.

Avior Wealth Management first reported a position in TGTX in Q2 2021 and held it in 4 quarters. The position peaked at $602K in Q3 2021. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

  • Avior Wealth Management reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 17 TG Therapeutics shares in Q1 2025, an estimated $511.
  • Avior Wealth Management first reported a position in TG Therapeutics in Q2 2021 and held it in 4 quarters.
  • Avior Wealth Management's TG Therapeutics position peaked at $602K in Q3 2021.
  • 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.